Morgan Stanley Cuts D.R. Horton Price Target to $130, Keeps Equalweight
Morgan Stanley lowered its price target on D.R. Horton to $130 from $151 and maintained its Equalweight rating.
Related stories
S&P 500 and Nasdaq Open Higher as Oil Prices Extend Declines
U.S. stocks opened higher as oil prices extended their declines, with midterm elections on the agenda.
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
Syra Health Reports Record Q3 Revenue and Gross Margin
Syra Health reported third-quarter 2026 revenue of $2.56 million, up 52% year over year, with a record 46.3% gross margin. It reported net income of $344,610 versus a loss a year e
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Rhythm Pharmaceuticals Shares Fall 8.7% After Q3 Net Loss
Rhythm Pharmaceuticals reported a net loss for the third quarter, and its shares fell 8.7%.
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
UL Solutions Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Sysco Reports First-Quarter Sales, Earnings Growth; Revises Sales Outlook
Sysco reported fiscal first-quarter sales of $21.7 billion, up 2.8%, and net earnings of $526 million, up 10.5% year over year. Adjusted EPS rose 3.5% to $1.19 and adjusted EBITDA
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC
Waters Corp Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:33 PM UTC